ALDH1 is identified as another biomarker for GBM; high levels of ALDH1 usually indicate high invasive features and resistance to EGFR inhibition (Smith et al., 2017; McKinney et al., 2019), characteristics that are used as a measure of stem-like properties for GBM. Here, EGFR is linked to glioblastoma.